How to choose the initial drug treatment for overactive bladder
- 39 Downloads
Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.
KeywordsLower Urinary Tract Symptom Overactive Bladder Oxybutynin Tamsulosin Tolterodine
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 5.Fantl J, Newman D, Colling J, et al.: Clinical Practice Guideline Number 2: Urinary Incontinence in Adults: Acute and Chronic Management. Rockville, MD: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1996 Update. [AHCPR publication 96-0682.]Google Scholar
- 13.O’Leary M, Erickson JR, Smith CP, et al.: Changes in voiding patterns in multiple sclerosis patients with controlled-release oxybutynin. Int J MS Care 2002, 4:116–119.Google Scholar
- 25.Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. Neurourol Urodyn 2002, 21:A445.Google Scholar
- 29.Kay G, Crook T, Rekeda L, et al.: Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50 :317–326.Google Scholar
- 30.Kay G, Kardiasmenos K, Crook T: Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract]. Presented at the International Continence Society Meeting. Christchurch, New Zealand; November 27–December 1, 2006.Google Scholar
- 32.Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. Presented at the 32nd Annual Meeting of the International Continence Society. Heidelberg, Germany; August 28–30, 2002.Google Scholar
- 33.Abrams P, Kaplan S, Millard R: Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Neurourol Urodyn 2001, 20:547–548.Google Scholar
- 35.MacDiarmid S, Chen A, Tu Nora, et al.: Effects of tamsulosin and extended-release oxybutynin on lower urinary tract symptoms in men [abstract 1639]. Presented at the American Urological Association Annual Meeting. Atlanta, GA; May 20–25, 2006.Google Scholar